Over millions of years of evolution, viruses have perfected their ability to modulate and hijack the cell functions for their own benefit.
ENYO Pharma’s founders have deciphered virus-host interactions and built a unique concept based on mimetism of the virus strategy for modulation of cellular functions. Thanks to a discovery engine, they are developing innovative drug discovery programs on many intracellular host targets yet untapped by pharma’s.
ENYO Pharma is currently focusing on hepatic diseases with two leading programs – chronic hepatitis B and NASH. Host-oriented ENYO Pharma’s drugs are also opening perspectives for a wide range of other therapeutic areas such as oncology.